• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Neuronetics Inc. (Amendment)

    2/14/24 10:21:36 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care
    Get the next $STIM alert in real time by email
    SC 13G/A 1 ccllc_STIM_13g02142024.htm SCHEDULE 13G/A
    
    
    

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549


    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO §240.13d-2

    (Amendment No.1)


    Neuronetics, Inc.

    (Name of Issuer)

    Common Stock, par value $0.01 per share

    (Title of Class of Securities)

    64131A105

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of This Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☑   Rule 13d-1(b)

    ☐   Rule 13d-1(c)

    ☐   Rule 13d-1(d)

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

         The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
    CUSIP No.64131A105 Page 2 of 7 Pages
    1

    NAMES OF REPORTING PERSONS

    J. Carlo Cannell

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ☐

    (b)  ☐

    3

    SEC USE ONLY

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    USA

    NUMBER OF SHARES

    BENEFICIALLY OWNED BY

    EACH REPORTING

    PERSON WITH

    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    2,769,268

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    2,769,268

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,769,268

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐

    (see instructions)

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

    9.57%

    12

    TYPE OF REPORTING PERSON

    IN, HC

     
    CUSIP No.64131A105 Page 3 of 7 Pages
    1

    NAMES OF REPORTING PERSONS

    Cannell Capital LLC

    I.R.S. Identification Nos. of Above Persons (Entities Only)

    94-3366999

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ☐

    (b)  ☐

    3

    SEC USE ONLY

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Wyoming, USA

    NUMBER OF SHARES

    BENEFICIALLY OWNED BY

    EACH REPORTING

    PERSON WITH

    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    2,769,268

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    2,769,268

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,769,268

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐

    (see instructions)

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

    9.57%

    12

    TYPE OF REPORTING PERSON

    IA

     
    CUSIP No.64131A105 Page 4 of 7 Pages
    Item 1.

    a)

    Name of Issuer

    Neuronetics, Inc.

    b)

    Address of issuer's principal executive offices:

    3222 Phoenixville Pike

    Malvern, PA 19355

    Item 2.

    a)

    Name of person filing:

    Cannell Capital LLC

    b)

    Address or principal business office or, if none, residence:

    245 Meriwether Circle

    Alta, WY 83414

    c)

    Citizenship:

    Wyoming, USA

    d)

    Title of class of securities:

    Common Stock

    e)

    CUSIP No.:

    64131A105

    Item 3.
    If this statement is filed pursuant to §240.13d-1(b) or §240.13d-2(b) or (c), check whether the person filing is a:

    (a)

    ☐

    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

    (b)

    ☐

    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

    (c)

    ☐

    Insurance company as defined in section 3(a)(19) of the Act(15 U.S.C. 78c).

    (d)

    ☐

    An Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

    (e)

    ☑

    An investment adviser in accordance with Section §240.13d-1(b)(1)(ii)(E).

    (f)

    ☐

    An Employee benefit plan or endowment fund in accordance with Section §240.13d-1(b)(1)(ii)(F).

    (g)

    ☐

    A Parent holding company or control person in accordance with Section §240.13d-1(b)(1)(ii)(G).

    (h)

    ☐

    A Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

    (i)

    ☐

    A Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3).

    (j)

    ☐

    A non-U.S. institution in accordance with Section §240.13d-1(b)(1)(ii)(J).

    (k)

    ☐

    Group, in accordance with Section §240.13d-1(b)(1)(ii)(J).

     
    CUSIP No.64131A105 Page 5 of 7 Pages
    Item 4. Ownership
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a)

    Amount beneficially owned: 2,769,268.

    (b)

    Percent of class: 9.57%.

    (c)

    Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote 0.
    (ii) Shared power to vote or to direct the vote 2,769,268.
    (iii) Sole power to dispose or to direct the disposition of 0.
    (iv) Shared power to dispose or to direct the disposition of 2,769,268. Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

    Item 5. Ownership of 5 Percent or Less of a Class.
    Not Applicable.

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
    Not Applicable.

    Item 8. Identification and Classification of Members of the Group.
    Not Applicable.

    Item 9. Notice of Dissolution of Group.
    Not Applicable.

    Item 10. Certifications.
    Not Applicable.

     
    CUSIP No.64131A105 Page 6 of 7 Pages

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    02/14/2024                            

    Date       

    By:  /s/ J. Carlo Cannell                 

    Name:  J. Carlo Cannell

    Cannell Capital LLC

    By:  /s/ J. Carlo Cannell                 

    Name:  J. Carlo Cannell

    Title:  Managing Member

     
    CUSIP No.64131A105 Page 7 of 7 Pages

    Exhibit A

    Agreement Regarding the Joint Filing of Schedule 13G

    The undersigned hereby agree as follows:
    1) Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached, and such Schedule 13G is filed on behalf each of them;
    2) Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

    By:  /s/ J. Carlo Cannell                 

    Name:  J. Carlo Cannell

    Cannell Capital LLC

    By:  /s/ J. Carlo Cannell                 

    Name:  J. Carlo Cannell

    Title:  Managing Member

    Get the next $STIM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STIM

    DatePrice TargetRatingAnalyst
    8/13/2024Outperform → Mkt Perform
    William Blair
    10/14/2021$18.00 → $12.00Market Outperform
    JMP Securities
    10/13/2021Outperform → Mkt Perform
    William Blair
    10/13/2021Buy → Neutral
    BTIG
    More analyst ratings

    $STIM
    SEC Filings

    View All

    SEC Form 144 filed by Neuronetics Inc.

    144 - Neuronetics, Inc. (0001227636) (Subject)

    8/8/25 4:54:08 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    SEC Form 424B5 filed by Neuronetics Inc.

    424B5 - Neuronetics, Inc. (0001227636) (Filer)

    8/6/25 4:30:21 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Neuronetics Inc.

    10-Q - Neuronetics, Inc. (0001227636) (Filer)

    8/5/25 7:31:19 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Madryn Asset Management, Lp sold $13,020,000 worth of shares (3,500,000 units at $3.72) (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    8/12/25 4:15:10 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Pfanstiel Steven

    3 - Neuronetics, Inc. (0001227636) (Issuer)

    7/15/25 5:00:06 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    EVP, CFO and Treasurer Pfanstiel Steven was granted 400,000 shares (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    7/15/25 5:00:04 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cascella Robert bought $75,000 worth of shares (100,000 units at $0.75), increasing direct ownership by 28% to 453,098 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    9/13/24 5:02:03 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Director Muir Glenn P bought $20,000 worth of shares (25,000 units at $0.80), increasing direct ownership by 9% to 289,818 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    9/6/24 5:05:03 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Director Muir Glenn P bought $21,250 worth of shares (25,000 units at $0.85), increasing direct ownership by 10% to 264,818 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    8/30/24 5:15:02 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Neuronetics downgraded by William Blair

    William Blair downgraded Neuronetics from Outperform to Mkt Perform

    8/13/24 10:26:16 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    JMP Securities reiterated coverage on Neuronetics with a new price target

    JMP Securities reiterated coverage of Neuronetics with a rating of Market Outperform and set a new price target of $12.00 from $18.00 previously

    10/14/21 8:41:45 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics downgraded by William Blair

    William Blair downgraded Neuronetics from Outperform to Mkt Perform

    10/13/21 12:25:53 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    MALVERN, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to six new employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient's continued service with the Company through the applicable vesting date, and the awards

    8/6/25 4:45:00 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics Reports Second Quarter 2025 Financial and Operating Results

    Delivered $38.1 million total revenue in the quarter, representing 18% adjusted pro forma revenue growth Generated record Greenbrook clinic revenue of $23.0 million in the quarter Reduced cash used in operations to $3.5 million, beating guidance of under $5 million In August 2025, received an additional $10 million in funding under the existing debt agreement with Perceptive Advisors LLC MALVERN, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ:STIM) (the "Company" or "Neuronetics") a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need he

    8/5/25 7:05:00 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics to Present at the Canaccord Genuity 45th Annual Growth Conference

    MALVERN, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that Keith Sullivan, President and Chief Executive Officer, will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025. The Company is scheduled to present at 1:30pm Eastern Time the same day.The presentation will be available via the conference portal to registered attendees and presenting companies for 14 days following th

    8/4/25 4:30:00 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    Leadership Updates

    Live Leadership Updates

    View All

    Neuronetics Appoints New Chief Financial Officer

    Steven Pfanstiel, a seasoned financial executive with extensive medical technology and pharmaceutical experience, replaces Steve Furlong as Chief Financial Officer following previously announced succession process Neuronetics reiterates guidance for second quarter and full year 2025 MALVERN, Pa., July 15, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that Steven Pfanstiel has been appointed as the company's new Chief Financial

    7/15/25 7:30:00 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics Set to Join Russell 2000® and Russell 3000® Indexes

    MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) --  Neuronetics, Inc. (NASDAQ:STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that it is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell indexes annual reconstitution, effective after the US market opens on June 30, 2025. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strate

    6/2/25 4:30:00 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Dr. Mehdi H. Shishehbor Appointed Chief Medical Officer of Inquis Medical

    Renowned vascular disease expert joins Silicon Valley clinical stage medical device company developing next-generation thrombectomy technology Inquis Medical also announces appointment of Bruce Shook, serial medtech entrepreneur, to Board of Directors REDWOOD CITY, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Inquis Medical, Inc., a privately held medical device company focused on peripheral vascular innovations, today announced the appointment of distinguished interventional cardiologist and scholar, Mehdi H. Shishehbor, DO, MPH, Ph.D., as Chief Medical Officer. Dr. Shishehbor is the President of University Hospitals Harrington Heart and Vascular Institute where he is the Angela and Ja

    7/12/23 9:00:00 AM ET
    $STIM
    $ABMD
    Medical/Dental Instruments
    Health Care

    $STIM
    Financials

    Live finance-specific insights

    View All

    Neuronetics to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call

    MALVERN, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release second quarter 2025 financial and operating results prior to market open on Tuesday, August 5, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/d6qidqaw. To listen to the conference call on your telephone, participants may register for t

    7/22/25 8:30:00 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics to Report First Quarter 2025 Financial and Operating Results and Host Conference Call

    MALVERN, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release first quarter 2025 financial and operating results prior to market open on Tuesday, May 6, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/knieqjnc. To listen to the conference call on your telephone, participants may register for the

    4/22/25 8:30:00 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call

    MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release fourth quarter 2024 financial and operating results prior to market open on Tuesday, March 4, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/a3eb5opb. To listen to the conference call on your telephone, participants may register fo

    2/21/25 8:30:00 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Neuronetics Inc.

    SC 13D - Neuronetics, Inc. (0001227636) (Subject)

    12/17/24 9:15:11 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neuronetics Inc.

    SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)

    11/14/24 1:42:23 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neuronetics Inc.

    SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)

    11/14/24 11:17:47 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care